Blog Elements
You can display blog posts in various ways with the “Blog Post” element/shortcode. You can see one example here and even more at the blog main menu item of this demo.
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Marco Chiumente
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Marco Chiumente2020-02-13 23:11:532022-04-12 11:42:11Ottimizzazione della terapia antiretrovirale in pazienti HIV positivi virosoppressi: studio osservazionale a lungo termine
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Mara Puglia
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Mara Puglia2020-02-04 13:34:282020-02-14 01:06:02COI e CDO per SIFaCT – Conflitto di interessi e di obbligazione per una società scientifica di farmacisti ospedalieri e dei servizi farmaceutici delle ASL
https://www.sifact.it/wp-content/uploads/2020/01/immagini.jpg
182
276
Mara Puglia
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Mara Puglia2020-01-30 15:56:442020-01-30 16:14:41Le raccomandazioni del Ministero della salute: aggiornamento ed evoluzione
https://www.sifact.it/wp-content/uploads/2020/01/Pubblicazioni.png
181
424
Marco Tedesco
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Marco Tedesco2020-01-26 22:38:032020-07-17 16:07:31Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression
https://www.sifact.it/wp-content/uploads/2020/01/Annotazione-2020-01-26-180624.jpg
308
902
Marco Tedesco
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Marco Tedesco2020-01-26 17:12:472020-01-26 20:57:03SIFaCT Insight gennaio 2020
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Mara Puglia
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Mara Puglia2020-01-24 12:36:082020-07-17 08:19:33Tisagenlecleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
Corso di aggiornamento “MASTERPHARM 2025 – 4a EDIZIONE – 1° modulo”, Baveno 14-16 maggio 2025